Ranbaxy merger showing sharp cons as well as pros for Sun Pharma

The merger with Ranbaxy by Sun Pharmaceuticals has given the company scale to move up the food chain in the industry but has also come at a cost to the enlarged entity, Business Today reports. The deal made Sun the world's fifth-largest generic drug maker and moved it up the corporate rankings in India but tied the company to Ranbaxy plants that have been banned by the U.S. FDA for not meeting quality standards. Legal fees, high staff costs and a one-time writedown of about $94 million hurt profitability, as did problems at one of the company's U.S. plants and declining prices in several categories, Business Today said. Report

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.